---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-008204"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T00:52:56.849541+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash

## Summary
- PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.
- Notes convertible at $1.18/share; warrants to buy up to ~8.5M FEMY shares at $1.18 and $1.475 per share.
- Interim CEO Josh Silverman will join Femasys' Board of Directors; collaboration agreement for joint research.
- PharmaCyte had $74.6M cash as of July 31, 2023; investment marks first external tech deployment.
- Femasys offers women's health products including late-stage FemBloc and FDA-cleared FemaSeed.

## SEC filing metadata
- accession: 0001683168-23-008204
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-008204
- JSON: https://secwatch.observer/filing/0001683168-23-008204.json
- Plain text: https://secwatch.observer/filing/0001683168-23-008204.txt

## Key facts
- Material Agreements
  PharmaCyte Biotech, Inc. entered into Collaboration Agreement with Femasys Inc. (effective 2023-11-14).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Femasys Inc.
  - Effective: 2023-11-14
  source text: ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm
- Material Agreements
  PharmaCyte Biotech, Inc. entered into Registration Rights Agreement with Femasys Inc..
  - Action: entry
  - Counterparty: Femasys Inc.
  source text: ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm
- Material Agreements
  PharmaCyte Biotech, Inc. entered into Purchase Agreement with Femasys Inc. valued at $5,000,000 (effective 2023-11-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Femasys Inc.
  - Value: $5,000,000
  - Effective: 2023-11-14
  source text: On November 14, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Femasys Inc. (“Femasys”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316823008204/0001683168-23-008204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.